FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary

A. Karara
{"title":"FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary","authors":"A. Karara","doi":"10.1186/s41120-016-0007-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":453,"journal":{"name":"AAPS Open","volume":"99 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS Open","FirstCategoryId":"1","ListUrlMain":"https://doi.org/10.1186/s41120-016-0007-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FDA原料药复合动物药指南草案:评论
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood Characterization, stability, and skin application of astaxanthin particulates A controlled vocabulary and taxonomy for the submission of quality attributes for therapeutic proteins An in-silico approach towards multivariate acceptable ranges in biopharmaceutical manufacturing Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1